CYNO Cynosure - Class A (MM)

WESTFORD, Mass., Sept. 21 /PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that it has entered into an agreement to become the exclusive technology provider for new skin treatment clinics being opened by sk:n Ltd. in the United Kingdom. Under the agreement, Cynosure will supply laser systems for all new sk:n clinics, which are expected to begin opening within the next year. These products include the Cynergy(R) workstation with MultiPlex(TM) technology vascular laser system, Affirm(TM) skin rejuvenation laser system, Apogee Elite(TM) hair removal system and Affinity QS(TM) tattoo removal laser. Under the agreement, Cynosure will train sk:n engineers in the use of the products and provide marketing support. "Further expansion in the European market is a key component of our strategy, so we are delighted about the opportunity to serve as the exclusive technology provider for a leader in the U.K. aesthetic market," said Cynosure Chairman and CEO Michael R. Davin. "We believe sk:n is aggressively building its brand in the U.K. to enable it to serve growing consumer demand for aesthetic skin treatments. We expect Cynosure's award-winning technologies to play an important role in supporting this growth." Andy Randall, managing director of sk:n Ltd., commented, "Our goal is to expand from our 17 current locations to over 50 sites over the next three years, and we must have the right technology partners to achieve that objective. I am pleased that our relationship with Cynosure will bring our clients a range of treatments such as laser hair and vein removal, and other anti-aging treatments using for example the Affirm. Cynosure's leading-edge technologies convinced us they are the ideal partner for us in our ambition to expand in the U.K market." About Cynosure, Inc. Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosurelaser.com/. About sk:n Laser Clinics sk:n is a leading provider of laser skin rejuvenation treatments and products in the U.K. With 17 clinics operating in the U.K. treating over 15,000 clients a month, sk:n plans to expand to 50 sites in the U.K. over the next three years. All sk:n clinics are fully registered with the UK Healthcare Commission, and three are located within NHS Trust Hospitals. Dermatologist Dr. Sean Lanigan is the group's medical director with clinical directors also in place at all locations, supported by consultant dermatologists, nurses and therapists. More information is available at http://www.lasercare-clinics.co.uk/. Safe Harbor Statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, its inability to control sk:n and ensure sk:n's performance of its obligations under the agreement, the inability to accurately predict the timing or outcome of regulatory decisions, timing of the company's launch of the Affirm system, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release. Contact: Scott Solomon Vice President Sharon Merrill Associates, Inc. 617-542-5300 DATASOURCE: Cynosure, Inc. CONTACT: Scott Solomon, Vice President, of Sharon Merrill Associates, Inc. for Cynosure, Inc., +1-617-542-5300, Web site: http://www.cynosurelaser.com/ http://www.lasercare-clinics.co.uk/

Copyright